A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2006 by Advanced-J.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Advanced-J
Collaborator:
Japan Heart Foundation
Information provided by:
Advanced-J
ClinicalTrials.gov Identifier:
NCT00144144
First received: September 1, 2005
Last updated: July 13, 2006
Last verified: July 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The antihypertensive effect of the increased dose of angiotensin II receptor blocker (AII antagonist) is compared with that of the additional combined use of amlodipine in hypertensive patients with Type 2 diabetes mellitus, who have been treated with AII antagonist, the antihypertensive effect of which has been inadequate.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypertension Diabetes Mellitus, Type 2 |
Drug: Angiotensin II receptor antagonists, Calcium channel blocker |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized, Controlled Study on Calcium Channel Blocker Versus Angiotensin II Antagonists in the Hypertensive Patients With Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure With Angiotension II Antagonists |
Resource links provided by NLM:
Further study details as provided by Advanced-J:
Primary Outcome Measures:
- Changes in blood pressure level at home after getting up.
- The rate of the blood pressure levels at home after getting up, which effected the target levels (systolic blood pressure < 125 mm Hg, diastolic blood pressure < 80 mm Hg).
- Adverse events, adverse drug reactions
- Clinical laboratory data
Secondary Outcome Measures:
- Changes in blood pressure levels measured on an outpatient basis.
- The rate of the blood pressure levels measured on an outpatient basis, which effected the standard levels (systolic blood pressure level <130 mm Hg, diastolic blood pressure level < 80 mm Hg).
- Changes in blood pressure levels measured at home before going to bed· Changes in IMT of the cervical artery
- Changes in PWV· Changes in echocardiographic findings
- Changes in urinary albumin level
- Changes in BNP· Changes in hs-CRP· Medical cost-effectiveness
| Estimated Enrollment: | 300 |
| Study Start Date: | September 2004 |
| Estimated Study Completion Date: | September 2008 |
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with type 2 diabetes mellitus.
- Patients who have been treated by the single use of AII antagonist at usual for at least 8 weeks or patients who have been treated by the combined use of AII antagonist at usual doses and calcium channel blocker or a antihypertensive drug other than ACE inhibitors for at least 8 weeks.
- Patients who show a systolic blood pressure (blood pressure) > 135 mm Hg or a diastolic blood pressure > 85 mm Hg, which is measured (in a sitting position) on an outpatient basis at the time of start of the observation period, and show the mean (blood pressure level measured at home after getting up before the start of study) of systolic blood pressure > 130 mm Hg or diastolic blood pressure > 80 mm Hg measured at home after getting up for last 5 days during the last 2-week observation period.
- Patients whose consent is obtained at age 20 years or over.
- Patients whose consent is obtained from themselves in written form. With regard to 2) and 3), however, the case, in which the mean of the systolic blood pressure levels measured at home after getting up for last 5 days during the first 1-week observation period is > 180 mm Hg or the mean diastolic blood pressure level is > 110 mm Hg, is included in the present study.
Exclusion Criteria:
- Patients with secondary hypertension.
- Patients who show a systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg on the measurement (in a sitting position) on an outpatient basis at the time of start of the observation period.
- Patients with severe hepatic dysfunction.
- Patients with severe renal dysfunction.
- Patients with a past history of hypersensitiveness to study drugs.
- Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant during the study period.
- Patients who have participated in the trial within 3 months before the start of the observation period or who attend the trial simultaneously with the present study.
- Other patients judged as being inappropriate for the subjects of the study by investigators.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00144144
Locations
| Japan | |
| Dept. of Clinical Immunology, Clinical Bioinformatics Research Unit, Graduate School of Medicine, the University of Tokyo | |
| Hongo, Bunkyo-ku, Tokyo, Japan, 113-8655 | |
Sponsors and Collaborators
Advanced-J
Japan Heart Foundation
Investigators
| Principal Investigator: | Ryuzo Kawamori, M.D. | Juntendo University School of Medicine, Dept. of Endocrinology and Metabolism |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00144144 History of Changes |
| Other Study ID Numbers: | ADVANCED-J01, UMIN-C000000017 |
| Study First Received: | September 1, 2005 |
| Last Updated: | July 13, 2006 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Keywords provided by Advanced-J:
|
Hypertension Diabetes Mellitus, Type 2 Calcium Channel Blocker Angiotensin II type 1 Receptor Blocker |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Hypertension Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Vascular Diseases Cardiovascular Diseases Angiotensin II Calcium, Dietary Calcium Channel Blockers |
Angiotensin Receptor Antagonists Angiotensin II Type 1 Receptor Blockers Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Bone Density Conservation Agents Physiological Effects of Drugs Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 19, 2013